← Back to Screener
Oculis Holding AG Ordinary shares (OCS)
Price$14.51
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)2.23%
Price vs S&P 500 (4W)-22.35%
VGM Score36.51
Market Capitalization$1.66B
All Metrics
Book Value / Share (Quarterly)$4.05
P/TBV (Annual)4.88x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.30
Price vs S&P 500 (YTD)2.76%
EPS (TTM)$-2.20
10-Day Avg Trading Volume0.66M
EPS Excl Extra (TTM)$-2.20
EPS (Annual)$-2.42
ROI (Annual)-49.88%
Cash / Share (Quarterly)$1.33
ROA (Last FY)-41.94%
EBITD / Share (TTM)$-1.93
Cash Flow / Share (Annual)$-1.48
P/B Ratio5.16x
P/B Ratio (Quarterly)5.38x
Net Income / Employee (Annual)$-2,109,708
Net Interest Coverage (TTM)-18.15x
ROA (TTM)-45.62%
EPS Incl Extra (Annual)$-2.42
Current Ratio (Annual)5.96x
Quick Ratio (Quarterly)5.10x
3-Month Avg Trading Volume0.40M
52-Week Price Return16.44%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.78
52-Week High$34.48
EPS Excl Extra (Annual)$-2.42
CapEx CAGR (5Y)133.49%
26-Week Price Return18.16%
Quick Ratio (Annual)5.85x
13-Week Price Return-24.29%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)5.18x
Enterprise Value$1.22B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.77
3-Month Return Std Dev70.45%
Net Income / Employee (TTM)$-2,016,713
ROE (Last FY)-50.47%
Net Interest Coverage (Annual)-9.77x
EPS Basic Excl Extra (Annual)$-2.42
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-2.20
Receivables Turnover (Annual)0.00x
ROI (TTM)-56.10%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.98
Price vs S&P 500 (52W)-11.77%
Year-to-Date Return13.70%
5-Day Price Return-23.01%
EPS Normalized (Annual)$-2.42
ROA (5Y Avg)-65.45%
Month-to-Date Return-17.38%
EBITD / Share (Annual)$-1.99
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.20
P/TBV (Quarterly)5.77x
P/B Ratio (Annual)4.55x
Book Value / Share (Annual)$4.27
Price vs S&P 500 (13W)-34.04%
Beta0.14x
Revenue / Share (TTM)$0.00
ROE (TTM)-56.78%
52-Week Low$16.00
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.63est. -0.54
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.33
4.33
4.33
4.33
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OCSOculis Holding AG Ordinary shares | — | — | D | $14.51 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Oculis Holding AG is a biopharmaceutical company developing topical treatments and disease-modifying therapies for ophthalmological conditions. Its pipeline includes OCS-01 for diabetic macular edema, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis and related neuro-ophthalmological disorders. The company's candidates target prevalent eye conditions including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.